文献速递浆细胞疾病造血干细胞移植与细胞治疗

大剂量白消安-美法仑对比美法仑联合强化VRD方案治疗新诊断多发性骨髓瘤:一项3期GEM试验

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.
PubMed 文献 · Blood · 2025-01-01

GEM12是一项3期试验,纳入458例适合自体干细胞移植的新诊断多发性骨髓瘤患者,随机接受白消安-美法仑(BUMEL,n=230)或美法仑200(MEL200,n=228)预处理。中位随访8.4年,BUMEL组中位无进展生存期89个月,MEL200组73.1个月(HR 0.89,95%CI 0.70-1.14;P=0.3),无显著差异;在ISS II/III期、t(14;16)和del(1p)患者中BUMEL显示获益。

要点

  • BUMEL组10⁻⁶ MRD阴性率68%,MEL200组58%(OR 1.51;P=0.035)。
  • BUMEL组中位PFS 89个月,MEL200组73.1个月(HR 0.89,95%CI 0.70-1.14;P=0.3)。
  • BUMEL在ISS II/III期、t(14;16)和del(1p)患者中显示获益。

核心结论

  • 中位随访8.4年,GEM2012试验显示新诊断多发性骨髓瘤患者中位PFS达89个月(BUMEL组),在晚期ISS分期患者中BUMEL显著优于MEL200。

研究设计与样本

  • GEM12是一项3期试验,纳入适合自体干细胞移植的新诊断多发性骨髓瘤患者,接受6个周期强化VRD诱导、BUMEL或MEL200预处理的自体干细胞移植及2个周期VRD巩固治疗。
  • 患者按开放标签2×2析因设计以1:1:1:1比例随机分组,以确保GEM12与后续3期GEM14试验之间的平衡。
  • 2013年至2015年间共随机458例患者(BUMEL组n=230;MEL200组n=228)。

主要发现

  • 10⁻⁶ MRD阴性率总体为63%,BUMEL组68% vs MEL200组58%(OR 1.51;P=0.035)。
  • BUMEL组中位PFS 89个月 vs MEL200组73.1个月(HR 0.89,95%CI 0.70-1.14;P=0.3)。
  • BUMEL在ISS II或III期、t(14;16)和del(1p)患者中显示获益。
  • ISS II或III期接受BUMEL及ISS I期接受MEL200的亚组中位PFS为96.5个月(95%CI 76至不可估计)。
  • 未观察到安全性问题。

关键数值与推荐

  • 10⁻⁶ MRD阴性率:BUMEL组68% vs MEL200组58%(OR 1.51;P=0.035)。
  • 中位PFS:BUMEL组89个月 vs MEL200组73.1个月(HR 0.89,95%CI 0.70-1.14;P=0.3)。
  • ISS II或III期接受BUMEL及ISS I期接受MEL200的亚组中位PFS为96.5个月(95%CI 76至不可估计)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In retrospective studies, autologous stem cell transplantation (ASCT) conditioning with intravenous busulfan and melphalan (BUMEL) led to longer progression-free survival (PFS) than melphalan alone (MEL200). We compared long-term outcomes of BUMEL vs MEL200 in the context of intensified bortezomib, lenalidomide, and dexamethasone (VRD) induction and consolidation therapies. GEM12 was a phase 3 trial for patients with newly diagnosed multiple myeloma (NDMM) eligible for ASCT including 6 reinforced VRD cycles followed by ASCT conditioned with BUMEL or MEL200 and 2 VRD consolidation cycles. The primary end point was PFS. Subgroup analyses were based on International Staging System (ISS) stages and high-risk genetic abnormalities. Patients were randomized with an open-label 2 × 2 factorial design and 1:1:1:1 allocation ratio to ensure the balance between the GEM12 and the subsequent phase 3 GEM14 trial. Between 2013 and 2015, 458 patients were randomized (BUMEL, n = 230; MEL200, n = 228). The 10⁻⁶ MRD-negative rate was 63%, 68% for BUMEL vs 58% for MEL200 (odds ratio, 1.51; P = .035). The median PFS was 89 months for BUMEL and 73.1 for MEL200 (hazard ratio, 0.89 [95% confidence interval, 0.70-1.14]; P = .3). BUMEL showed benefit for patients with ISS stages II or III, t(14;16), and del(1p). For subcohorts ISS stages II or III treated with BUMEL and ISS I treated with MEL200 the median PFS was 96.5 months (95% confidence interval, 76 to not estimable). No safety concerns were observed. After a median follow-up of 8.4 years, GEM2012 demonstrated one of the longest PFS values reported in patients with NDMM, with significant differences favoring BUMEL in advanced ISS stages. The trial was registered at www.ClinicalTrials.gov as #NCT01916252 and at European Union Drug Regulating Authorities Clinical Trials as EudraCT 2012-005683-10.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lahuerta JJ, San-Miguel J, Jiménez-Ubieto A, et al. High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial. Blood. 2025. PMID: 40499010. doi:10.1182/blood.2025028313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。